Transcriptomic profiling identifies Thai TNBC patients who may benefit ICI and PARPi
As we all know that breast cancer is a very problematic disease in Thai women. Although over 90% of the patients can be cured from the disease, many patients suffer from a recurrent disease. This is because breast cancer is not just one type of disease, but rather very complex and vastly different from patient to patient, especially the very aggressive type called triple-negative breast cancer (TNBC).
As a result, we wanted to have a deeper understanding on the TNBC on why patients receiving the same treatment regimens respond differently and whether there are promising treatments other than chemotherapy for these patients. In this study, we performed gene expression analysis using nCounter-based technology to further classify Thai TNBC into 4 subgroups (SiSPTNBC Group 1-4). We showed that there were signatures in each of the subgroup that could be predictors for some new targeted therapies. For example, patients classified as Group 2 showed specific immune cell signature and might benefit from immune checkpoint inhibitor treatment while PAPR inhibitors might benefit the patients in Group 1 or 2.
For more details on the study, please see the following link:
